Warren-based Tevogen announced it has extended its lease agreement and is expanding its corporate headquarters in Warren — more than doubling its footprint.
The expanded space will centralize cross-functional teams, including executive leadership, regulatory affairs, corporate strategy, and research and development (previously located in Philadelphia), thereby increasing operational efficiency and enhancing cross-team collaboration.
The headquarters will also house Tevogen.AI and the Generics & Biosimilars initiative, with dedicated facilities for Tevogen.AI’s growing team of data scientists and engineers as development of its proprietary AdapTcell and PredicTcell algorithms accelerates.
In addition to these core initiatives, the expanded facility could provide capacity to support potential new business units as Tevogen continues to grow and diversify its portfolio.
The newly leased space was formerly occupied by CAPTRUST, a national investment advisory firm with reported total client assets exceeding $1 trillion. Tevogen is proud to continue building in this high-profile location and expresses its sincere appreciation to the building’s owner, Mitsui Sumitomo Insurance Company of America, and parent company MS&AD Insurance Group Holdings Inc., for their continued support.
“This expansion will provide the infrastructure needed to support two of our evolving initiatives, Tevogen.AI and Generics & Biosimilars,” Dr. Ryan Saadi, CEO of Tevogen Bio said. “From advancing domestic pharmaceutical manufacturing to harnessing the power of AI in drug discovery, these programs reflect our commitment to building a more resilient and accessible health care system.”
